SPOTLIGHT -
EP. 1: When to Start Systemic Treatment in Newly Diagnosed RCC
EP. 2: Goals of Therapy in Advanced RCC
EP. 3: Determining Initial Therapeutic Approach in Advanced RCC
EP. 4: Choosing Among TKIs in Advanced RCC
EP. 5: RCC First-Line Toxicity Considerations
EP. 6: Assessing Treatment Response with RCC First-Line Therapies
EP. 7: Advanced RCC Sequencing Challenges
EP. 8: Patient Selection and Checkpoint Inhibition in RCC
EP. 9: The Rationale for Cabozantinib in Advanced RCC
EP. 10: Options in the Third Line Setting for RCC
EP. 11: The Role of Lenvatinib in Advanced RCC
EP. 12: Second and Third-Line Decisions in RCC
EP. 13: Long-Term RCC Data with Nivolumab
EP. 14: Novel Approaches in Advanced RCC
EP. 15: A Changing Landscape in RCC
EP. 16: A Look to the Future in RCC
Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors
Navigating Systemic Therapy for RCC: Balancing Risk Status and Response
ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC
Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making
